Comparing intramuscular meglumine antimoniate with oral chloroquine in the treatment of cutaneous leishmaniasis: A randomized controlled trail
Journal of Pakistan Association of Dermatologists · 02.07.2024 · 34 (3) · 599-605
DOI: 10.66344/jpad.v34i3.2702 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pakistan Association of Dermatologists, online erschienen am 02.07.2024. Verfasst von Majid Paracha und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cutaneous leishmaniasis (CL) is highly prevalent in developing countries, including Pakistan. The conventional treatment for CL, meglumine antimoniate (MA), is unfortunately associated with considerable toxicity. Studies of alternative treatment options have reported inconsistent results. This study aimed to quantitatively compare the effectiveness of intramuscular MA with oral chloroquine in the treatment of CL.
Methods
Patients of both genders between the ages of 06-60 years, presenting with CL lesions of less than 03 months duration were enrolled in this randomized controlled trial (RCT), carried out from August 2021 to February 2022 at the Department of Dermatology, Lady Reading Hospital, Peshawar. CL patients with a history of prior treatment and/or those with comorbidities were excluded. Eligible patients were allocated randomly into two groups, where patients in Group I were given intramuscular MA (20 mg/Kg body weight once daily for 4 weeks) while patients in Group II were given oral chloroquine (250 mg, twice daily over 4 weeks). The treatment response was assessed at 4-week follow-up after completion of the treatment.
Results
The enrolled CL patients (n=82) were equally divided in two groups. The age and gender was evenly distributed between the two groups. The mean patient’s age in Group I and II was 36.49±13.22 years and 37.34±13.19 years, whilst the male to female ratio was 1.28 and 1.16, respectively. Results showed a significantly higher rate of complete treatment response in Group I compared to Group II (78% vs. 48.8%, p=0.006). Treatment responses in both groups were also stratified on the basis of gender and socioeconomic status.
Conclusion
This study indicated significantly higher efficacy of intramuscular MA compared to oral chloroquine for CL treatment.
Zitieren
APA
Paracha, M., Wasim, M., Noor, S. M., Khan, A. Q., & Ahmad, I. (2024). Comparing intramuscular meglumine antimoniate with oral chloroquine in the treatment of cutaneous leishmaniasis: A randomized controlled trail. Journal of Pakistan Association of Dermatologists, 34(3), 599-605. https://doi.org/10.66344/jpad.v34i3.2702
Vancouver
Paracha M, Wasim M, Noor SM, Khan AQ, Ahmad I. Comparing intramuscular meglumine antimoniate with oral chloroquine in the treatment of cutaneous leishmaniasis: A randomized controlled trail. Journal of Pakistan Association of Dermatologists. 2024;34(3):599-605. doi:10.66344/jpad.v34i3.2702
BibTeX
@article{Paracha2024,
author = {Paracha, Majid and Wasim, Muhammad and Noor, Sahibzada Mahmood and Khan, Abdul Qayum and Ahmad, Iftikhar},
title = {Comparing intramuscular meglumine antimoniate with oral chloroquine in the treatment of cutaneous leishmaniasis: A randomized controlled trail},
journal = {Journal of Pakistan Association of Dermatologists},
year = {2024},
volume = {34},
number = {3},
pages = {599--605},
doi = {10.66344/jpad.v34i3.2702}
}
EUVIMED